Formulations comprising recombinant acid alpha-glucosidase
TW202629239APending Publication Date: 2026-07-16AMICUS THERAPEUTICS INC
View PDF 0 Cites 0 Cited by
Patent Information
- Application Number
- TW114148574
- Authority / Receiving Office
- TW · TW
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2017-02-10
- Filing Date
- 2017-03-30
- Publication Date
- 2026-07-16
Abstract
Provided are pharmaceutical formulations comprising a recombinant acid α-glucosidase, wherein the recombinant acid α-glucosidase is expressed in Chinese hamster ovary (CHO) cells and comprises an increased content of N-glycan units bearing one or two mannose-6-phosphate residues when compared to a content of N-glycan units bearing one or two mannose-6-phosphate residues of alglucosidase alfa; at least one buffer selected from the group consisting of a citrate, a phosphate and combinations thereof; and at least one excipient selected from the group consisting of mannitol, polysorbate 80, and combinations thereof, wherein the formulation has a pH of from about 5.0 to about 7.0. Also provided are methods of treating Pompe disease using these pharmaceutical formulations.
Need to check novelty before this filing date? Find Prior Art